Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Short-term glucocorticoids decrease insulin secretion in type 2 diabetes
Last updated August 15, 2026
Key finding
The increase in AUC Glucose was significantly higher (p = 0.016) in the T2DM group.
This study examined the effects of short-term high-dose glucocorticoid exposure on beta-cell function in adults with type 2 diabetes, finding significant changes in glucose and insulin metrics.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study examined the effects of short-term high-dose glucocorticoid exposure on beta-cell function in adults with type 2 diabetes, finding significant changes in glucose and insulin metrics.
Clinical relevance
Understanding the impact of glucocorticoids on beta-cell function is crucial for managing diabetes treatment. These findings highlight the need for careful consideration of glucocorticoid use in patients with type 2 diabetes, as it may exacerbate insulin resistance and hyperglycemia.
Keep in mind
Non-randomized study design may introduce bias. Limited sample size affects generalizability. Short duration of glucocorticoid exposure may not reflect long-term effects.
Published in
Journal Reference
Publication details and source links for this paper.
Monica S, May MA, Bettina T, Yannis G, Leon F, Zhiming Z. Impact of short-term high-dose glucocorticoid exposure on beta-cell function in type 2 diabetes. PLOS ONE. 2020;15(5):e0231190. doi:10.1371/journal.pone.0231190
Main Effects
AUC glucose increased significantly in the T2DM group (p = 0.016).
C-peptide AUC decreased significantly in the T2DM group.
Insulinogenic index decreased significantly in the T2DM group (69.2% vs 34.3%, p = 0.008).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Prednisone 40 mg daily for 3 days and C-peptide, Change in insulinogenic index from baseline to week 12, Glucose area under the curve (AUC), and 3 more.
This study contributes evidence to
Primary intervention
Prednisone 40 mg daily for 3 days
Primary outcomes
- C-peptide
- Change in insulinogenic index from baseline to week 12
- Glucose area under the curve (AUC)
Evidence topics
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 59
1
Related topics
6
Evidence pairs
274
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Glycemic Control
matched_outcome
Core evidence
Study findings
The primary outcomes reported in this study.
Change in insulinogenic index from baseline to week 12
Prednisone 40 mg daily for 3 days → Change in insulinogenic index from baseline to week 12
Prednisone 40 mg daily for 3 days → Change in insulinogenic index from baseline to week 12
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerGlucose area under the curve (AUC)
Prednisone 40 mg daily for 3 days → Glucose area under the curve (AUC)
Prednisone 40 mg daily for 3 days → Glucose area under the curve (AUC)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerInsulin resistance
Prednisone 40 mg daily for 3 days → Insulin resistance
Prednisone 40 mg daily for 3 days → Insulin resistance
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPostprandial insulin AUC
Prednisone 40 mg daily for 3 days → Postprandial insulin AUC
Prednisone 40 mg daily for 3 days → Postprandial insulin AUC
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- AUC glucose increased by 117.3 mmol/L/min in the T2DM group (p = 0.016).
- C-peptide AUC decreased by 49.4 nmol/L/min.
- Insulinogenic index decreased by 42.2% (p = 0.008).
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients undergoing treatment that includes glucocorticoids.
Keep in Mind
- Results may not be applicable to all populations with diabetes.
- Further research is needed to confirm long-term effects.
- The study's findings are based on a small sample size.
Between the Lines
- Non-randomized study design may introduce bias.
- Limited sample size affects generalizability.
- Short duration of glucocorticoid exposure may not reflect long-term effects.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Prednisone 40 mg daily for 3 days and C-peptide, Prednisone 40 mg daily for 3 days and Postprandial and OGTT Glucose.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
C-peptide Evidence Hub
All studies measuring C-peptide
1 studies
outcome_hubMeasures C-peptide as a key outcome.
Postprandial and OGTT Glucose Evidence Hub
All studies measuring Postprandial and OGTT Glucose
1 studies
outcome_hubMeasures Postprandial and OGTT Glucose as a key outcome.
Prednisone 40 mg daily for 3 days Evidence Hub
All studies on Prednisone 40 mg daily for 3 days
1 studies
intervention_hubContributes to Prednisone 40 mg daily for 3 days evidence base.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Prednisone 40 mg daily for 3 days and C-peptide
Intervention: Prednisone 40 mg daily for 3 daysOutcome: C-peptide
1 results
All studies on Prednisone 40 mg daily for 3 days and Glucose area under the curve (AUC)
Intervention: Prednisone 40 mg daily for 3 daysOutcome: Glucose area under the curve (AUC)
1 results
All studies on Prednisone 40 mg daily for 3 days
Intervention: Prednisone 40 mg daily for 3 days
1 results
All studies measuring C-peptide
Outcome: C-peptide
1 results
All studies measuring Glucose area under the curve (AUC)
Outcome: Glucose area under the curve (AUC)
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Prednisone 40 mg daily for 3 days improve c-peptide?
Emerging Evidence
Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for C-peptide.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
C-peptide
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Prednisone 40 mg daily for 3 days improve homa-b?
Emerging Evidence
Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for HOMA-B.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HOMA-B
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Prednisone 40 mg daily for 3 days improve insulin resistance?
Emerging Evidence
Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for Insulin resistance.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Insulin resistance
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Prednisone 40 mg daily for 3 days improve postprandial insulin auc?
Emerging Evidence
Current evidence does not show a clear benefit of Prednisone 40 mg daily for 3 days for Postprandial insulin AUC.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Postprandial insulin AUC
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
All studies on Prednisone 40 mg daily for 3 days and C-peptideAll studies on Prednisone 40 mg daily for 3 days and Change in insulinogenic index from baseline to week 12All studies on Prednisone 40 mg daily for 3 days and Glucose area under the curve (AUC)All studies on Prednisone 40 mg daily for 3 days and HOMA-B
Related research
Read related research summaries.
Nutritional Therapy and AGIs Improve Postprandial Glucose in DiabetesWeight Loss Methods Improve Insulin Resistance in Type 2 DiabetesAerobic exercise lowers blood glucose more than resistance exercise in T2 diabetes.Daixie Decoction Improves Glycemic Control in Type 2 DiabetesDate seed powder improves diabetes management
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.